Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study

F. Palandri, G. Auteri, E. Abruzzese, G. Caocci, M. Bonifacio, F. Mendicino, R. Latagliata, A. Iurlo, F. Branzanti, B. Garibaldi,M. M. Trawinska, D. Cattaneo, M. Krampera,O. Mulas, E. A. Martino, M. Cavo, N. Vianelli,S. Impera,F. Efficace,F. Heidel,M. Breccia, E. M. Elli,G. A. Palumbo

Annals of Hematology（2024）

引用 0|浏览1

暂无评分

摘要

Ruxolitinib is beneficial in patients with myelofibrosis (MF) and polycythemia vera (PV). Information on ruxolitinib adherence is scant. The Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera (RAMP) prospective multicenter study (NCT06078319) included 189 ruxolitinib-treated patients. Patients completed the Adherence to Refills and Medications Scale (ARMS) and Distress Thermometer and Problem List (DTPL) at the earliest convenience, after registration in the study, and at later timepoints. At week-0, low adherence (ARMS > 14) and high distress (DT ≥ 4) were declared by 49.7

查看译文

关键词

Adherence to medication,Ruxolitinib,Myelofibrosis,Polycythemia Vera,Distress,Adherence

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要